Intensity Therapeutics, Inc. Common stock
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical tr… Read more
Intensity Therapeutics, Inc. Common stock (INTS) - Total Assets
Latest total assets as of September 2025: $9.59 Million USD
Based on the latest financial reports, Intensity Therapeutics, Inc. Common stock (INTS) holds total assets worth $9.59 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Intensity Therapeutics, Inc. Common stock - Total Assets Trend (2019–2024)
This chart illustrates how Intensity Therapeutics, Inc. Common stock’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Intensity Therapeutics, Inc. Common stock - Asset Composition Analysis
Current Asset Composition (December 2024)
Intensity Therapeutics, Inc. Common stock's total assets of $9.59 Million consist of 70.3% current assets and 29.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 54.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Intensity Therapeutics, Inc. Common stock's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Intensity Therapeutics, Inc. Common stock's current assets represent 70.3% of total assets in 2024, a decrease from 96.0% in 2019.
- Cash Position: Cash and equivalents constituted 54.2% of total assets in 2024, up from 42.5% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Intensity Therapeutics, Inc. Common stock Competitors by Total Assets
Key competitors of Intensity Therapeutics, Inc. Common stock based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Intensity Therapeutics, Inc. Common stock - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Intensity Therapeutics, Inc. Common stock generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Intensity Therapeutics, Inc. Common stock is currently not profitable relative to its asset base.
Intensity Therapeutics, Inc. Common stock - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.60 | 1.63 | 7.04 |
| Quick Ratio | 3.60 | 1.63 | 6.88 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $5.91 Million | $ 1.47 Million | $ 8.13 Million |
Intensity Therapeutics, Inc. Common stock - Advanced Valuation Insights
This section examines the relationship between Intensity Therapeutics, Inc. Common stock's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.10 |
| Latest Market Cap to Assets Ratio | 3.14 |
| Asset Growth Rate (YoY) | -72.3% |
| Total Assets | $4.78 Million |
| Market Capitalization | $15.03 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Intensity Therapeutics, Inc. Common stock's assets at a significant premium ( 3.14x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Intensity Therapeutics, Inc. Common stock's assets decreased by 72.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Intensity Therapeutics, Inc. Common stock (2019–2024)
The table below shows the annual total assets of Intensity Therapeutics, Inc. Common stock from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $4.78 Million | -72.34% |
| 2023-12-31 | $17.30 Million | +884.35% |
| 2022-12-31 | $1.76 Million | -66.32% |
| 2021-12-31 | $5.22 Million | -48.61% |
| 2020-12-31 | $10.15 Million | +12.70% |
| 2019-12-31 | $9.01 Million | -- |